Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Comera Life Sciences Holdings, Inc.CMRA · Entity 94670 | Member of 10% owner group | December 29, 2023 | February 03, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Comera Life Sciences Holdings, Inc.
Report date December 29, 2023 · Filed February 03, 2024
Jointly reported with Konar Shameek
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| 12.0% Senior Secured Convertible NotesSEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2024-12-29 | IndirectBy Regolith Capital Investments L.P. | Not disclosed |
Reported balance
After 2023-12-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-12-29 · Purchase · Acquired Not disclosed · Balance Not disclosed F1: Regolith Capital Investments, L.P. ("Regolith") entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which Regolith acquired (i) $112,500 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the "Notes") and (ii) 4,090,908 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share ("Common Stock"), at an exercise price of $0.055 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. F2: The reporting persons are general partners of Regolith and disclaim beneficial ownership of the securities held by Regolith except to the extent of their pecuniary interest therein |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2028-12-29 | IndirectBy Regolith Capital Investments L.P. | 4,090,908 |
Reported balance
After 2023-12-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-12-29 · Purchase · Acquired 4,090,908 · Balance 4,090,908 F1: Regolith Capital Investments, L.P. ("Regolith") entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which Regolith acquired (i) $112,500 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the "Notes") and (ii) 4,090,908 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share ("Common Stock"), at an exercise price of $0.055 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. F2: The reporting persons are general partners of Regolith and disclaim beneficial ownership of the securities held by Regolith except to the extent of their pecuniary interest therein |
Filing footnotes · ownership attribution and instrument terms
F1: Regolith Capital Investments, L.P. ("Regolith") entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which Regolith acquired (i) $112,500 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the "Notes") and (ii) 4,090,908 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share ("Common Stock"), at an exercise price of $0.055 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof.
F2: The reporting persons are general partners of Regolith and disclaim beneficial ownership of the securities held by Regolith except to the extent of their pecuniary interest therein
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 29, 2023 Filed Feb 3, 2024 00:48 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | PurchaseWarrants to Purchase Common Stock · Derivative | 4,090,908 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001104659-24-010258 · tm245098-2_4seq1.xml · derivative · entry 2 Konar Shameek · CIK 0001465302 · Member of 10% owner group Konar Victoria · CIK 0002010586 · Member of 10% owner group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Regolith Capital Investments L.P. Disclosed balance after: 4,090,908 Underlying: Common Stock · 4,090,908 shares Expires 2028-12-29 F1 · kind: Regolith Capital Investments, L.P. ("Regolith") entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which Regolith acquired (i) $112,500 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the "Notes") and (ii) 4,090,908 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share ("Common Stock"), at an exercise price of $0.055 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. F1 · price: Regolith Capital Investments, L.P. ("Regolith") entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which Regolith acquired (i) $112,500 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the "Notes") and (ii) 4,090,908 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share ("Common Stock"), at an exercise price of $0.055 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. F2 · ownership.nature: The reporting persons are general partners of Regolith and disclaim beneficial ownership of the securities held by Regolith except to the extent of their pecuniary interest therein Read SEC document |
| December 29, 2023 Filed Feb 3, 2024 00:48 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | Purchase12.0% Senior Secured Convertible Notes · Derivative | Not disclosed | $112,500.00 Strike: $0.06 | $112,500.00 |
DisclosureSEC source: 0001104659-24-010258 · tm245098-2_4seq1.xml · derivative · entry 1 Konar Shameek · CIK 0001465302 · Member of 10% owner group Konar Victoria · CIK 0002010586 · Member of 10% owner group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Regolith Capital Investments L.P. Disclosed balance after: Not disclosed Underlying: Common Stock · 2,045,454 shares Expires 2024-12-29 F1 · kind: Regolith Capital Investments, L.P. ("Regolith") entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which Regolith acquired (i) $112,500 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the "Notes") and (ii) 4,090,908 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share ("Common Stock"), at an exercise price of $0.055 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. F2 · ownership.nature: The reporting persons are general partners of Regolith and disclaim beneficial ownership of the securities held by Regolith except to the extent of their pecuniary interest therein Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.